SCHEMBL7146714

SCHEMBL7146714

Cc1ccccc1NS(=O)(=O)CCSc1nc2ccccc2s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
HSD17B10 Q99714 2/20 0.62
LMNA P02545 6/20 0.61
MAPT P10636 2/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
SMN1; SMN2 Q16637 5/20 0.58
KMT2A Q03164 2/20 0.58
HTT P42858 1/20 0.58
CYP1A2 P05177 4/20 0.55
CYP2D6 P10635 3/20 0.55
CYP2C19 P33261 3/20 0.50
CYP3A4 P08684 2/20 0.50
HTR1A P08908 1/20 0.50
HTR2A P28223 1/20 0.50
HTR7 P34969 1/20 0.50
CYP2C9 P11712 1/20 0.50
STAT6 P42226 1/20 0.50
HPGD P15428 2/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151670 0.93 LMNA (0.65) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7148438 0.92 LMNA (0.64) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7144723 0.89 LMNA (0.49) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7147603 0.88 LMNA (0.57) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7149622 0.85 ALDH1A1 (0.59) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7154156 0.85 MAPT (0.48) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7150889 0.84 ALDH1A1 (0.62) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7149883 0.83 LMNA (0.53) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7150789 0.82 MAPT (0.43) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7153854 0.82 LMNA (0.52) ALDH1A1HSD17B10LMNAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885HSD17B10 2088/4885LMNA 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.